Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Digestive Diseases and Sciences
Published in: Digestive Diseases and Sciences 11/2023

Open Access 11-09-2023 | Chronic Inflammatory Bowel Disease | Review

Irritable Bowel Syndrome-Like Symptoms in Quiescent Inflammatory Bowel Disease: A Practical Approach to Diagnosis and Treatment of Organic Causes

Authors: Jane Lim, Ali Rezaie

Published in: Digestive Diseases and Sciences | Issue 11/2023

Login to get access

Abstract

Background

Despite achieving remission in inflammatory bowel disease (IBD), persistent gastrointestinal symptoms are common in quiescent IBD. While irritable bowel syndrome (IBS) is commonly diagnosed in IBD, IBS-like symptoms of recurrent abdominal pain and altered bowel habits can also be attributed to a wide range of overlapping gastrointestinal (GI) etiologies and systemic disorders with GI manifestations that often do not respond to conventional IBS therapies. Delay in diagnosis of these conditions can lead to ongoing patient suffering, reduced quality of life, repetition of invasive testing, increased healthcare utilization, and potentially unnecessary empirical escalation of IBD-related treatments.

Aims

This review provides a practical approach for the evaluation and diagnosis of IBS mimickers in IBD. We summarize the definition, pathophysiology, diagnosis and treatment of the potential etiologies causing unexplained GI symptoms.

Conclusion

Overlapping conditions can co-exist with IBD and explain IBS-like symptoms. The diagnostic work-up in this population should be individualized and tailored to the predominant symptom pattern, associated clinical signs and symptoms and predisposing conditions that can be obtained from a detailed history and physical examination.
Literature
1.
Fairbrass KM, Costantino SJ, Gracie DJ, Ford AC. Prevalence of irritable bowel syndrome-type symptoms in patients with inflammatory bowel disease in remission: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2020;5:1053–1062.PubMedCrossRef
2.
Abdalla MI, Sandler RS, Kappelman MD, Martin CF, Chen W, Anton K et al. Prevalence and impact of inflammatory bowel disease-irritable bowel syndrome on patient-reported outcomes in CCFA partners. Inflamm Bowel Dis. 2017;23:325–331.PubMedCrossRef
3.
Pimentel M, Saad RJ, Long MD, Rao SSC. ACG clinical guideline: small intestinal bacterial overgrowth. Am J Gastroenterol. 2020;115:165–178.PubMedCrossRef
4.
Lee JM, Lee KM, Chung YY, Lee YW, Kim DB, Sung HJ et al. Clinical significance of the glucose breath test in patients with inflammatory bowel disease. J Gastroenterol Hepatol. 2015;30:990–994.PubMedCrossRef
5.
6.
Ghoshal UC, Yadav A, Fatima B, Agrahari AP, Misra A. Small intestinal bacterial overgrowth in patients with inflammatory bowel disease: a case-control study. Indian J Gastroenterol. 2022;41:96–103.PubMedCrossRef
7.
Shah A, Morrison M, Burger D, Martin N, Rich J, Jones M et al. Systematic review with meta-analysis: the prevalence of small intestinal bacterial overgrowth in inflammatory bowel disease. Aliment Pharmacol Ther. 2019;49:624–635.PubMedCrossRef
8.
Rezaie A, Buresi M, Lembo A, Lin H, McCallum R, Rao S et al. Hydrogen and methane-based breath testing in gastrointestinal disorders: the North American consensus. The American journal of gastroenterology. 2017;112:775–784.PubMedPubMedCentralCrossRef
9.
Cangemi DJ, Lacy BE, Wise J. Diagnosing small intestinal bacterial overgrowth: a comparison of lactulose breath tests to small bowel aspirates. Dig Dis Sci. 2021;66:2042–2050.PubMedCrossRef
10.
Gu P, Patel D, Lakhoo K, Ko J, Liu X, Chang B et al. Breath Test Gas patterns in inflammatory bowel disease with concomitant irritable bowel syndrome-like symptoms: a controlled large-scale database linkage analysis. Dig Dis Sci. 2020;65:2388–2396.PubMedCrossRef
11.
Pimentel M, Constantino T, Kong Y, Bajwa M, Rezaei A, Park S. A 14-day elemental diet is highly effective in normalizing the lactulose breath test. Dig Dis Sci. 2004;49:73–77.PubMedCrossRef
12.
Ghoshal UC, Sachdeva S, Ghoshal U, Misra A, Puri AS, Pratap N et al. Asian-Pacific consensus on small intestinal bacterial overgrowth in gastrointestinal disorders: an initiative of the Indian neurogastroenterology and motility association. Indian J Gastroenterol. 2022;41:483–507.PubMedPubMedCentralCrossRef
13.
Pimentel M, Morales W, Lezcano S, Sun-Chuan D, Low K, Yang J. Low-dose nocturnal tegaserod or erythromycin delays symptom recurrence after treatment of irritable bowel syndrome based on presumed bacterial overgrowth. Gastroenterol Hepatol (N Y). 2009;5:435–442.PubMed
14.
Gandhi A, Shah A, Jones MP, Koloski N, Talley NJ, Morrison M et al. Methane positive small intestinal bacterial overgrowth in inflammatory bowel disease and irritable bowel syndrome: a systematic review and meta-analysis. Gut Microbes. 2021;13:1933313.PubMedPubMedCentralCrossRef
15.
Pimentel M, Lin HC, Enayati P, van den Burg B, Lee HR, Chen JH et al. Methane, a gas produced by enteric bacteria, slows intestinal transit and augments small intestinal contractile activity. Am J Physiol Gastrointest Liver Physiol. 2006;290:G1089–G1095.PubMedCrossRef
16.
Takakura W, Pimentel M, Rao S, Villanueva-Millan MJ, Chang C, Morales W et al. A single fasting exhaled methane level correlates with fecal methanogen load, clinical symptoms and accurately detects intestinal methanogen overgrowth. Am J Gastroenterol. 2022;117:470–477.PubMedCrossRef
17.
Dridi B, Fardeau ML, Ollivier B, Raoult D, Drancourt M. The antimicrobial resistance pattern of cultured human methanogens reflects the unique phylogenetic position of archaea. J Antimicrob Chemother. 2011;66(9):2038–2044.PubMedCrossRef
18.
Low K, Hwang L, Hua J, Zhu A, Morales W, Pimentel M. A combination of rifaximin and neomycin is most effective in treating irritable bowel syndrome patients with methane on lactulose breath test. J Clin Gastroenterol. 2010;44:547–550.PubMedCrossRef
19.
20.
Schulze J, Sonnenborn U. Yeasts in the gut: from commensals to infectious agents. Dtsch Arztebl Int. 2009;106:837–842.PubMedPubMedCentral
21.
Rao SSC, Tan G, Abdulla H, Yu S, Larion S, Leelasinjaroen P. Does colectomy predispose to small intestinal bacterial (SIBO) and fungal overgrowth (SIFO)? Clin Transl Gastroenterol. 2018;9:146.PubMedPubMedCentralCrossRef
22.
Liu S, Zhao W, Lan P, Mou X. The microbiome in inflammatory bowel diseases: from pathogenesis to therapy. Protein Cell. 2021;12:331–345.PubMedCrossRef
23.
Sokol H, Leducq V, Aschard H, Pham HP, Jegou S, Landman C et al. Fungal microbiota dysbiosis in IBD. Gut. 2017;66:1039–1048.PubMedCrossRef
24.
Li XV, Leonardi I, Putzel GG, Semon A, Fiers WD, Kusakabe T et al. Immune regulation by fungal strain diversity in inflammatory bowel disease. Nature. 2022;603:672–678.PubMedPubMedCentralCrossRef
25.
Iliev ID, Funari VA, Taylor KD, Nguyen Q, Reyes CN, Strom SP et al. Interactions between commensal fungi and the C-type lectin receptor dectin-1 influence colitis. Science. 2012;336:1314–1317.PubMedPubMedCentralCrossRef
26.
Ferwerda B, Ferwerda G, Plantinga TS, Willment JA, van Spriel AB, Venselaar H et al. Human dectin-1 deficiency and mucocutaneous fungal infections. N Engl J Med. 2009;361:1760–1767.PubMedPubMedCentralCrossRef
27.
Glocker EO, Hennigs A, Nabavi M, Schaffer AA, Woellner C, Salzer U et al. A homozygous CARD9 mutation in a family with susceptibility to fungal infections. N Engl J Med. 2009;361:1727–1735.PubMedPubMedCentralCrossRef
28.
Taylor PR, Tsoni SV, Willment JA, Dennehy KM, Rosas M, Findon H et al. Dectin-1 is required for beta-glucan recognition and control of fungal infection. Nat Immunol. 2007;8:31–38.PubMedCrossRef
29.
McGovern DP, Gardet A, Torkvist L, Goyette P, Essers J, Taylor KD et al. Genome-wide association identifies multiple ulcerative colitis susceptibility loci. Nat Genet. 2010;42:332–337.PubMedPubMedCentralCrossRef
30.
Franke A, Balschun T, Sina C, Ellinghaus D, Hasler R, Mayr G et al. Genome-wide association study for ulcerative colitis identifies risk loci at 7q22 and 22q13 (IL17REL). Nat Genet. 2010;42:292–294.PubMedCrossRef
31.
Bogatyrev SR, Leite G, Pimentel M, Mathur R, Hosseini A, Rashid M, et al. Increased fungal loads detected in duodenal aspirates using multiplexed digital polymerase chainr eaction are associated with more severe upper respiratory symptoms and abdominal pain. [Abstract]. In press 2023.
32.
Friedman M, Ramsay DB, Borum ML. An unusual case report of small bowel Candida overgrowth as a cause of diarrhea and review of the literature. Dig Dis Sci. 2007;52:679–680.PubMedCrossRef
33.
Allegretti JR, Kassam Z, Chan WW. Small intestinal bacterial overgrowth: should screening be included in the pre-fecal microbiota transplantation evaluation? Dig Dis Sci. 2018;63:193–197.PubMedCrossRef
34.
35.
36.
Vijayvargiya P, Camilleri M. Update on bile acid malabsorption: finally ready for prime time? Curr Gastroenterol Rep. 2018;20:10.PubMedCrossRef
37.
Sauter GH, Munzing W, von Ritter C, Paumgartner G. Bile acid malabsorption as a cause of chronic diarrhea: diagnostic value of 7alpha-hydroxy-4-cholesten-3-one in serum. Dig Dis Sci. 1999;44:14–19.PubMedCrossRef
38.
Barrett JS, Irving PM, Shepherd SJ, Muir JG, Gibson PR. Comparison of the prevalence of fructose and lactose malabsorption across chronic intestinal disorders. Aliment Pharmacol Ther. 2009;30:165–174.PubMedCrossRef
39.
40.
Ramos LR, Sachar DB, DiMaio CJ, Colombel JF, Torres J. Inflammatory bowel disease and pancreatitis: a review. J Crohns Colitis. 2016;10:95–104.PubMedCrossRef
41.
Maconi G, Dominici R, Molteni M, Ardizzone S, Bosani M, Ferrara E et al. Prevalence of pancreatic insufficiency in inflammatory bowel diseases Assessment by fecal elastase-1. Dig Dis Sci. 2008;53:262–70.PubMedCrossRef
42.
Fousekis FS, Theopistos VI, Katsanos KH, Christodoulou DK. Pancreatic involvement in inflammatory bowel disease: a review. J Clin Med Res. 2018;10:743–751.PubMedPubMedCentralCrossRef
43.
Massironi S, Fanetti I, Vigano C, Pirola L, Fichera M, Cristoferi L et al. Systematic review-pancreatic involvement in inflammatory bowel disease. Aliment Pharmacol Ther. 2022;55:1478–1491.PubMedPubMedCentralCrossRef
44.
Lohr JM, Dominguez-Munoz E, Rosendahl J, Besselink M, Mayerle J, Lerch MM et al. United European gastroenterology evidence-based guidelines for the diagnosis and therapy of chronic pancreatitis (HaPanEU). United European Gastroenterol J. 2017;5:153–199.PubMedPubMedCentralCrossRef
45.
Dominguez-Munoz JE. Diagnosis and treatment of pancreatic exocrine insufficiency. Curr Opin Gastroenterol. 2018;34:349–354.PubMedCrossRef
46.
Dellon ES, Gonsalves N, Abonia JP, Alexander JA, Arva NC, Atkins D et al. International consensus recommendations for eosinophilic gastrointestinal disease nomenclature. Clin Gastroenterol Hepatol. 2022;20:2474-2484 e3.PubMedCrossRef
47.
Walker MM, Potter M, Talley NJ. Eosinophilic gastroenteritis and other eosinophilic gut diseases distal to the oesophagus. Lancet Gastroenterol Hepatol. 2018;3:271–280.PubMedCrossRef
48.
Walsh RE, Gaginella TS. The eosinophil in inflammatory bowel disease. Scand J Gastroenterol. 1991;26:1217–1224.PubMedCrossRef
49.
Tozlu M, Cash B, Younes M, Ertan A. Dilemma in post-IBD patients with IBS-D symptoms: a 2020 overview. Expert Rev Gastroenterol Hepatol. 2021;15:5–8.PubMedCrossRef
50.
Klein NC, Hargrove RL, Sleisenger MH, Jeffries GH. Eosinophilic gastroenteritis. Medicine (Baltimore). 1970;49:299–319.PubMedCrossRef
51.
Dellon ES, Gonsalves N, Rothenberg ME, Hirano I, Chehade M, Peterson KA et al. Determination of biopsy yield that optimally detects eosinophilic gastritis and/or duodenitis in a randomized trial of lirentelimab. Clin Gastroenterol Hepatol. 2022;20:535-545 e15.PubMedCrossRef
52.
53.
Castells M, Butterfield J. Mast cell activation syndrome and mastocytosis: initial treatment options and long-term management. J Allergy Clin Immunol Pract. 2019;7:1097–1106.PubMedCrossRef
54.
55.
Fan L, Wong M, Fan XS, Hong Y, Sun K, Jiang C et al. Quantitative analysis of intramucosal mast cells in irritable bowel syndrome: a comparison with inflammatory bowel disease in remission. J Clin Gastroenterol. 2021;55:244–249.PubMedCrossRef
56.
Gelbmann CM, Mestermann S, Gross V, Kollinger M, Scholmerich J, Falk W. Strictures in Crohn’s disease are characterised by an accumulation of mast cells colocalised with laminin but not with fibronectin or vitronectin. Gut. 1999;45:210–217.PubMedPubMedCentralCrossRef
57.
Weinstock LB, Pace LA, Rezaie A, Afrin LB, Molderings GJ. Mast cell activation syndrome: a primer for the gastroenterologist. Dig Dis Sci. 2021;66:965–982.PubMedCrossRef
58.
Bassotti G, Villanacci V, Nascimbeni R, Cadei M, Manenti S, Sabatino G et al. Colonic mast cells in controls and slow transit constipation patients. Aliment Pharmacol Ther. 2011;34:92–99.PubMedCrossRef
59.
60.
DiBaise JK, Harris LA, Goodman B. Postural tachycardia syndrome (POTS) and the GI tract: a primer for the gastroenterologist. Am J Gastroenterol. 2018;113:1458–1467.PubMedCrossRef
61.
Afrin LB, Fox RW, Zito SL, Choe L, Glover SC. Successful targeted treatment of mast cell activation syndrome with tofacitinib. Eur J Haematol. 2017;99:190–193.PubMedCrossRef
62.
Molderings GJ, Brettner S, Homann J, Afrin LB. Mast cell activation disease: a concise practical guide for diagnostic workup and therapeutic options. J Hematol Oncol. 2011;4:10.PubMedPubMedCentralCrossRef
63.
64.
Sapone A, Lammers KM, Casolaro V, Cammarota M, Giuliano MT, De Rosa M et al. Divergence of gut permeability and mucosal immune gene expression in two gluten-associated conditions: celiac disease and gluten sensitivity. BMC Med. 2011;9:23.PubMedPubMedCentralCrossRef
65.
Naik RD, Seidner DL, Adams DW. Nutritional consideration in celiac disease and nonceliac gluten sensitivity. Gastroenterol Clin North Am. 2018;47:139–154.PubMedCrossRef
66.
Volta U, Caio G, De Giorgio R, Henriksen C, Skodje G, Lundin KE. Non-celiac gluten sensitivity: a work-in-progress entity in the spectrum of wheat-related disorders. Best Pract Res Clin Gastroenterol. 2015;29:477–491.PubMedCrossRef
67.
Mastoroudes H, Giarenis I, Cardozo L, Srikrishna S, Vella M, Robinson D et al. Prolapse and sexual function in women with benign joint hypermobility syndrome. BJOG. 2013;120:187–192.PubMedCrossRef
68.
Fikree A, Aktar R, Grahame R, Hakim AJ, Morris JK, Knowles CH et al. Functional gastrointestinal disorders are associated with the joint hypermobility syndrome in secondary care: a case-control study. Neurogastroenterol Motil. 2015;27:569–579.PubMedCrossRef
69.
Vounotrypidis P, Efremidou E, Zezos P, Pitiakoudis M, Maltezos E, Lyratzopoulos N et al. Prevalence of joint hypermobility and patterns of articular manifestations in patients with inflammatory bowel disease. Gastroenterol Res Pract. 2009;2009:924138.PubMedCrossRef
70.
Zarate N, Farmer AD, Grahame R, Mohammed SD, Knowles CH, Scott SM et al. Unexplained gastrointestinal symptoms and joint hypermobility: is connective tissue the missing link? Neurogastroenterol Motil. 2010;22:252-e78.PubMedCrossRef
71.
Thwaites PA, Gibson PR, Burgell RE. Hypermobile Ehlers-Danlos syndrome and disorders of the gastrointestinal tract: what the gastroenterologist needs to know. J Gastroenterol Hepatol. 2022;37:1693–709.PubMedPubMedCentralCrossRef
72.
Malfait F, Francomano C, Byers P, Belmont J, Berglund B, Black J et al. The 2017 international classification of the Ehlers-Danlos syndromes. Am J Med Genet C Semin Med Genet. 2017;175:8–26.PubMedCrossRef
73.
74.
Kohn A, Chang C. The relationship between hypermobile Ehlers-Danlos syndrome (hEDS), postural orthostatic tachycardia syndrome (POTS), and mast cell activation syndrome (MCAS). Clin Rev Allergy Immunol. 2020;58:273–97.PubMedCrossRef
75.
Freeman R, Wieling W, Axelrod FB, Benditt DG, Benarroch E, Biaggioni I et al. Consensus statement on the definition of orthostatic hypotension, neurally mediated syncope and the postural tachycardia syndrome. Clin Auton Res. 2011;21:69–72.PubMedCrossRef
76.
Loavenbruck A, Iturrino J, Singer W, Sletten DM, Low PA, Zinsmeister AR et al. Disturbances of gastrointestinal transit and autonomic functions in postural orthostatic tachycardia syndrome. Neurogastroenterol Motil. 2015;27:92–8.PubMedCrossRef
77.
Wang LB, Culbertson CJ, Deb A, Morgenshtern K, Huang H, Hohler AD. Gastrointestinal dysfunction in postural tachycardia syndrome. J Neurol Sci. 2015;359:193–6.PubMedCrossRef
78.
Thieben MJ, Sandroni P, Sletten DM, Benrud-Larson LM, Fealey RD, Vernino S et al. Postural orthostatic tachycardia syndrome: the Mayo clinic experience. Mayo Clin Proc. 2007;82:308–13.PubMedCrossRef
79.
Moris D, Chakedis J, Rahnemai-Azar AA, Wilson A, Hennessy MM, Athanasiou A et al. Postoperative abdominal adhesions: clinical significance and advances in prevention and management. J Gastrointest Surg. 2017;21:1713–22.PubMedCrossRef
80.
Parker MC, Wilson MS, Menzies D, Sunderland G, Clark DN, Knight AD et al. The SCAR-3 study: 5-year adhesion-related readmission risk following lower abdominal surgical procedures. Colorectal Dis. 2005;7:551–8.PubMedCrossRef
81.
Pichetshote N, Rezaie A. Bloating and abdominal distension: exploring hidden depths and insights. Currrent Treatment Options in Gastroenterology. 2020;18:337–52.CrossRef
82.
Bove GM, Chapelle SL, Hanlon KE, Diamond MP, Mokler DJ. Attenuation of postoperative adhesions using a modeled manual therapy. PLoS One. 2017;12:e0178407.PubMedPubMedCentralCrossRef
83.
Wasserman JB, Copeland M, Upp M, Abraham K. Effect of soft tissue mobilization techniques on adhesion-related pain and function in the abdomen: a systematic review. J Bodyw Mov Ther. 2019;23:262–9.PubMedCrossRef
84.
Tabibian N, Swehli E, Boyd A, Umbreen A, Tabibian JH. Abdominal adhesions: a practical review of an often overlooked entity. Ann Med Surg (Lond). 2017;15:9–13.PubMedPubMedCentralCrossRef
85.
Chiaffarino F, Cipriani S, Ricci E, Roncella E, Mauri PA, Parazzini F et al. Endometriosis and inflammatory bowel disease: a systematic review of the literature. Eur J Obstet Gynecol Reprod Biol. 2020;252:246–51.PubMedCrossRef
86.
Jess T, Frisch M, Jorgensen KT, Pedersen BV, Nielsen NM. Increased risk of inflammatory bowel disease in women with endometriosis: a nationwide Danish cohort study. Gut. 2012;61:1279–83.PubMedCrossRef
87.
de Silva PS, Hansen HH, Wehberg S, Friedman S, Norgard BM. Risk of ectopic pregnancy in women with inflammatory bowel disease: a 22-year nationwide cohort study. Clin Gastroenterol Hepatol. 2018;16:83-89 e1.PubMedCrossRef
88.
Young S, Burns MK, DiFrancesco L, Nezhat A, Nezhat C. Diagnostic and treatment guidelines for gastrointestinal and genitourinary endometriosis. J Turk Ger Gynecol Assoc. 2017;18:200–9.PubMedPubMedCentralCrossRef
89.
Veeraswamy A, Lewis M, Mann A, Kotikela S, Hajhosseini B, Nezhat C. Extragenital endometriosis. Clin Obstet Gynecol. 2010;53:449–66.PubMedCrossRef
90.
Maroun P, Cooper MJ, Reid GD, Keirse MJ. Relevance of gastrointestinal symptoms in endometriosis. Aust N Z J Obstet Gynaecol. 2009;49:411–4.PubMedCrossRef
91.
Schink M, Konturek PC, Herbert SL, Renner SP, Burghaus S, Blum S et al. Different nutrient intake and prevalence of gastrointestinal comorbidities in women with endometriosis. J Physiol Pharmacol. 2019;70:10–26402.
92.
93.
Hudelist G, English J, Thomas AE, Tinelli A, Singer CF, Keckstein J. Diagnostic accuracy of transvaginal ultrasound for non-invasive diagnosis of bowel endometriosis: systematic review and meta-analysis. Ultrasound Obstet Gynecol. 2011;37:257–63.PubMedCrossRef
94.
95.
96.
Perera LP, Ananthakrishnan AN, Guilday C, Remshak K, Zadvornova Y, Naik AS et al. Dyssynergic defecation: a treatable cause of persistent symptoms when inflammatory bowel disease is in remission. Dig Dis Sci. 2013;58:3600–5.PubMedCrossRef
97.
Rezaie A, Gu P, Kaplan GG, Pimentel M, Al-Darmaki AK. Dyssynergic defecation in inflammatory bowel disease: a systematic review and meta-analysis. Inflammatory Bowel Diseases. 2018;24:1065–73.PubMedCrossRef
98.
Quinn KP, Tse CS, Lightner AL, Pendegraft RS, Enders FT, Raffals LE. Nonrelaxing pelvic floor dysfunction is an underestimated complication of ileal pouch-anal anastomosis. Clin Gastroenterol Hepatol. 2017;15:1242–7.PubMedCrossRef
99.
Quinn KP, Lightner AL, Faubion WA, Raffals LE. A comprehensive approach to pouch disorders. Inflamm Bowel Dis. 2019;25:460–71.PubMedCrossRef
100.
Stellingwerf ME, Maeda Y, Patel U, Vaizey CJ, Warusavitarne J, Bemelman WA et al. The role of the defaecating pouchogram in the assessment of evacuation difficulty after restorative proctocolectomy and pouch-anal anastomosis. Colorectal Dis. 2016;18:O292-300.PubMedCrossRef
101.
Mikami Y, Tsunoda J, Suzuki S, Mizushima I, Kiyohara H, Kanai T. Significance of 5-aminosalicylic acid intolerance in the clinical management of ulcerative colitis. Digestion. 2023;104:58–65.PubMedCrossRef
Metadata
Title
Irritable Bowel Syndrome-Like Symptoms in Quiescent Inflammatory Bowel Disease: A Practical Approach to Diagnosis and Treatment of Organic Causes
Authors
Jane Lim
Ali Rezaie
Publication date
11-09-2023
Publisher
Springer US
Published in
Digestive Diseases and Sciences / Issue 11/2023
Print ISSN: 0163-2116
Electronic ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-023-08095-w

Other articles of this Issue 11/2023

Digestive Diseases and Sciences 11/2023 Go to the issue

Original Article

Mitochondrial DNA Copy Number, a Damage-Associated Molecular Pattern Molecule, Can Predict Pancreatic Necrosis and Is Correlated with the Severity of Acute Pancreatitis

DDS-SIRC Cooperative Conferences

Sizzling Fat—Curative Endoscopic Resection of a Giant Lipoma Causing Colo-Colic Intussusception

Original Article

First Clostridioides difficile Recurrence Is Highest Following Concomitant Antimicrobial Administration During and Within 30 Days of Treatment

Review

Introducing Molecular Chaperones into the Causality and Prospective Management of Autoimmune Hepatitis

Original Article

Lifestyle Factors Associated with Abdominal Pain in Quiescent Inflammatory Bowel Disease

Original Article

Anlotinib Attenuates Liver Fibrosis by Regulating the Transforming Growth Factor β1/Smad3 Signaling Pathway
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits